NCT03412786View on ClinicalTrials.gov

Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

December 8, 2021

Study Completion Date

December 8, 2021

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

Bcl-Xl_42-CAF09b vaccine

The vaccine consists of 0.05 mg peptide (bcl-xl\_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion

Trial Locations (1)

2730

Herlev Hospital, Herlev

All Listed Sponsors
lead

Herlev Hospital

OTHER

NCT03412786 - Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases | Biotech Hunter | Biotech Hunter